P/E at 33.83 vs Industry's 31.56: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amid Sector Norms

The P/E ratio of Sun Pharmaceutical Industries Ltd at 33.83 is above the industry average of 31.56, indicating that the stock commands a valuation premium of roughly 7.2%. This premium suggests that investors are willing to pay more for each rupee of earnings compared to the broader Pharmaceuticals & Biotechnology sector. Such a premium often reflects expectations of superior earnings growth, stronger market positioning, or better financial health. However, it also implies that the stock may be more sensitive to earnings disappointments or sector headwinds. Sun Pharmaceutical Industries Ltd’s market capitalisation stands at ₹4,13,057.51 crores, categorising it firmly as a large-cap stock within the sector.

Performance Across Timeframes: Mixed Momentum Signals

Examining the stock’s returns reveals a nuanced picture. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a modest 4.21% gain, slightly underperforming the Sensex’s 4.54% rise. However, the short-term performance is more intriguing. The stock has declined by 4.76% over the last month, significantly underperforming the Sensex’s marginal -0.47% loss. Yet, over the three-month period, the stock’s loss of 0.49% is far less severe than the Sensex’s 7.63% drop, indicating some resilience in recent months. Year-to-date, the stock has managed a slight positive return of 0.10%, contrasting with the Sensex’s 9.41% decline. This divergence between short-term weakness and medium-term relative strength raises questions about the underlying drivers — Sun Pharmaceutical Industries Ltd’s recent price action may reflect sector-specific factors or company-specific developments that have tempered volatility compared to the broader market. Is this short-term softness a temporary correction or a sign of deeper challenges?

Moving Average Configuration: Signs of a Complex Trend

The technical setup of Sun Pharmaceutical Industries Ltd reveals a mixed trend. The stock price currently sits above its 200-day moving average, a long-term bullish indicator, but remains below the 5-day, 20-day, 50-day, and 100-day moving averages. This configuration suggests that while the stock has maintained a long-term support level, it is experiencing short to medium-term pressure. The fact that it is below all short and intermediate moving averages indicates recent weakness or consolidation, possibly signalling a pause or correction within a broader uptrend. The two-day consecutive decline with a cumulative fall of 0.5% adds to the short-term caution. Could this be a consolidation phase before a renewed advance, or is it the start of a more sustained downtrend?

Relative Performance: Outperforming Over Longer Horizons

Looking beyond the one-year horizon, Sun Pharmaceutical Industries Ltd has demonstrated strong relative performance. Over three years, the stock has surged 70.16%, significantly outpacing the Sensex’s 29.03% gain. The five-year return is even more impressive at 170.28%, compared to the Sensex’s 55.68%. However, the ten-year return of 112.07% trails the Sensex’s 212.89%, reflecting a period of underperformance in the more distant past. This long-term outperformance in recent years may justify the current valuation premium, as investors reward sustained earnings growth and market share gains. Does this historical outperformance support a higher valuation multiple today?

Sector Context: Pharmaceuticals & Biotechnology Performance Snapshot

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently. While some companies have posted gains, others have faced headwinds from regulatory challenges and pricing pressures. Sun Pharmaceutical Industries Ltd’s relative resilience in the three-month period, with a loss of only 0.49% compared to the sector’s more pronounced declines, highlights its defensive qualities within the sector. The stock’s ability to maintain a position above its 200-day moving average further underscores its relative strength. Sector-wide, the balance of positive, flat, and negative performers remains varied, reflecting ongoing uncertainty in global pharmaceutical markets.

Rating Reassessment: Previously Hold, Now Updated

On 23 Feb 2026, Sun Pharmaceutical Industries Ltd’s rating was updated from a previous Hold status. While the current rating is not disclosed, the reassessment reflects a fresh analysis of the company’s valuation, financial health, and technical signals. The previous Mojo Score of 72.0 and the large-cap market cap grade provide a solid foundation for this review. What is the current rating, and how does it factor in the valuation premium and recent performance trends?

Conclusion: A Complex Valuation and Performance Landscape

The data for Sun Pharmaceutical Industries Ltd paints a picture of a stock trading at a modest premium to its sector, supported by strong medium to long-term performance but facing short-term technical headwinds. The mixed moving average configuration, with the price above the 200-day but below shorter-term averages, suggests a nuanced trend that requires close monitoring. The divergence between short-term weakness and relative resilience over three months and year-to-date periods adds complexity to the analysis. The recent rating reassessment from Hold invites further scrutiny — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →